EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Harold Wilson-Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E Wechsler iD, Salman Siddiqui iD

Allergy · 2026-08 · 81 (8) · 2775-2791

DOI: 10.1111/all.70215 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 23.01.2026. Verfasst von Harold Wilson-Morkeh und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Churg-Strauss Syndrome, Granulomatosis with Polyangiitis, Immunomodulation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly eosinophilic inflammation, B‐cell mediated autoimmunity, neutrophil activation, and the generation of pathogenic anti‐neutrophil cytoplasmic antibodies, all of which can contribute to tissue/organ damage. High‐dose glucocorticoids are the mainstay treatment for EGPA, but over the past two decades the development of biologic treatments targeting interleukin (IL)‐5, eosinophils and B‐cells has revitalized the treatment landscape. Mepolizumab, a humanized monoclonal antibody that specifically targets IL‐5, and benralizumab, which targets the IL‐5 receptor (IL‐5Rα), are both approved for the treatment of patients with non‐severe relapsing or refractory EGPA. In Phase III trials, these biologics have demonstrated favorable safety profiles and efficacy, with treatment leading to remission induction, remission maintenance, and oral glucocorticoid sparing benefits. However, as understanding of the full complexity of EGPA pathogenesis improves, new treatment targets are emerging. Consequently, understanding key pathogenic mechanisms at the patient level, enabling a more tailored treatment approach, is an important goal for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Churg-Strauss SyndromeGranulomatosis with PolyangiitisImmunomodulationHumansMolecular Targeted TherapyAntibodies, Monoclonal, HumanizedEosinophilsTreatment OutcomeTranslational Research, BiomedicalAnimalsSignal Transduction

Stichwörter der Autor:innen

autoimmunitybiologicseosinophilsvasculitis

Substanzen

Antibodies, Monoclonal, Humanizedmepolizumab

Autor:innen und Institutionen

  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Department of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado, USA.
  • Division of Rheumatology and Clinical Immunology, Medical University of Graz, Graz, Austria.
  • Global Medical Affairs, GSK, Rio de Janeiro, Brazil.
  • Department of Rheumatology and Clinical Immunology, Medical Center-University of Freiburg, Freiburg, Germany.
  • Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology, and Diabetology, Medius Klinik Kirchheim, Academic Teaching Hospital, University of Tübingen, Tübingen, Germany.

ORCID-Profile: Michael E Wechsler, Salman Siddiqui

Förderung

  • GlaxoSmithKline

Zitieren

APA

Wilson-Morkeh, H., Seluk, L., Bosch, P., Aguiar, C., Thiel, J., Hellmich, B., Wechsler, M. E., & Siddiqui, S. (2026). Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice. Allergy, 81(8), 2775-2791. https://doi.org/10.1111/all.70215

Vancouver

Wilson-Morkeh H, Seluk L, Bosch P, Aguiar C, Thiel J, Hellmich B, et al. Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice. Allergy. 2026;81(8):2775-2791. doi:10.1111/all.70215

BibTeX
@article{WilsonMorkeh2026,
  author = {Wilson-Morkeh, Harold and Seluk, Lior and Bosch, Philipp and Aguiar, Carolina and Thiel, Jens and Hellmich, Bernhard and Wechsler, Michael E and Siddiqui, Salman},
  title = {Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {8},
  pages = {2775--2791},
  doi = {10.1111/all.70215}
}
Kostenlos starten →